Preferred method for treating respiratory diseases by using L-salbutamol sulfate

A kind of albuterol and disease technology, applied in the field of medicine

Active Publication Date: 2021-03-23
SUZHOU JUNNING NEW MEDICINE DEV CENT CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is an unmet clinical need to develop L-salbutamol sulfate into granules to achieve the effect of treating respiratory diseases such as asthma and COPD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preferred method for treating respiratory diseases by using L-salbutamol sulfate
  • Preferred method for treating respiratory diseases by using L-salbutamol sulfate
  • Preferred method for treating respiratory diseases by using L-salbutamol sulfate

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0021] Example 1: Clinical application of L-sulphate albuterol granules and tablets in the treatment of bronchial asthma and asthmatic bronchitis

[0022] Take random, double-blind, parallel control, multi-center clinical study, tablet enrolls 197 cases altogether, wherein test group (L-salbutamol sulfate tablet) 99 cases, control group (B group) 98 cases. L-salbutamol sulfate tablet 2mg is used for the treatment of bronchial asthma and chronic asthmatic bronchitis Compared with commercially available racemic salbutamol sulfate tablet 4mg, its dosage is 1 / 2 of racemic salbutamol sulfate tablet. Observe the clinical control rate, total effective rate and incidence of adverse reactions of patients after administration.

[0023] A randomized, open, parallel controlled, multi-center clinical study was adopted. A total of 99 cases of L-salbutamol sulfate granules (Group C) were enrolled, and its dosage of 2 mg was 1 / 2 of that of racemic salbutamol sulfate tablets. Observe the clin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preferred method for treating clinical diseases by using levosalbutamol sulfate oral granules so as to reduce adverse reactions and improve safety.

Description

technical field [0001] The invention belongs to the field of medicine, and specifically relates to a method for preparing oral granules using L-R-salbutamol salt and auxiliary materials or a combination thereof for the treatment of clinical diseases to reduce adverse reaction rates and improve safety. Background technique [0002] Salbutamol sulfate (racemate) has been used clinically for nearly forty years. According to statistics, this drug is the most common drug used clinically in the treatment of bronchial asthma. Studies have shown that salbutamol sulfate is a racemate of R-type and S-type, R-type is an isomer with expansion effect, and S-type has no similar biological activity. In clinical application, racemic albuterol sulfate exhibits adverse reactions such as tracheal allergic reaction, abnormal bronchoconstriction and bronchial inflammation. These adverse reactions may be related to the effect of the S-isomer. Experiments also showed that the bronchodilation ef...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/16A61K31/137A61K45/06A61K47/26A61P1/00A61P11/00A61P11/06A61P17/06A61P37/02
CPCA61K9/1623A61K31/137A61K45/06A61P11/06A61P11/00A61P1/00A61P17/06A61P37/02A61K2300/00
Inventor 张睿谭律雅徐玲
Owner SUZHOU JUNNING NEW MEDICINE DEV CENT CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap